Prime Medicine Inc. (PRME)
2.40
-0.12 (-4.76%)
At close: Mar 03, 2025, 12:06 PM
Company Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.
It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine Inc.
| Country | United States |
| IPO Date | Oct 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 234 |
| CEO | Dr. Keith Michael Gottesdiener M.D., Ph.D. |
Contact Details
Address: 21 Erie Street Cambridge, Massachusetts United States | |
| Website | https://www.primemedicine.com |
Stock Details
| Ticker Symbol | PRME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517936 |
| CUSIP Number | 74168J101 |
| ISIN Number | US74168J1016 |
| Employer ID | 00-0000000 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Dr. Keith Michael Gottesdiener M.D., Ph.D. | President, Chief Executive Officer, Secretary & Director |
| Dr. Allan Reine M.D. | Chief Financial Officer |
| Carman Alenson CPA, M.B.A. | Senior Vice President of Finance & Chief Accounting Officer |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Prime Editing Platform |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer |
| Dr. David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer |
| Dr. Karen Brown J.D., Ph.D. | Senior Vice President of Intellectual Property & Legal Affairs |
| Dr. Meredith Goldwasser | Senior Vice President and Head of Strategy & Corporate Operations |
| Niamh Alix | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | 485BPOS | Filing |
| Feb 28, 2025 | 485BXT | Filing |
| Feb 28, 2025 | S-8 | Filing |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 13, 2025 | 497K | Filing |
| Feb 13, 2025 | 497 | Filing |
| Feb 13, 2025 | 497K | Filing |
| Feb 13, 2025 | 497 | Filing |